Ae1 Ae3 Antibody Bafilomycin A1 Bile Acid Assay Bioassay Blog cDNA Ch 223191 Choline Acetyltransferase Antibody Deoxycholic Acid Sodium Salt ELISA kit Epz 6438 exosome F Actin Antibody Glycodeoxycholic Acid Hdac Activity Assay immune Isotype Ldn 193189 Medium Mip 1B Mmp Activity Assay Mothers Against Decapentaplegic Mouse Albumin Elisa Pamabrom 100Mg Pepstatin A peptide Phospho 4Ebp1 Polyclonal Purification Ru 58841 Soft Agar Sr 9011 Trypsin Activity Assay Tubastatin A Uric Acid Assay Valproic Acid Sodium Salt Western Blot
Effects of Fruquintinib on the Pluripotency Maintenance and Differentiation Potential of Mouse Embryonic Stem Cells
Mouse embryonic stem cells (mESCs) can keep self-renewal and differentiate into any cell kind of the three main germ layers. The vascular endothelial progress issue (VEGF) is concerned within the regulation of mESC differentiation and induces the activation of a collection of kinase responses and several other cell signaling pathways by binding to its respective transmembrane receptors, vascular endothelial progress issue receptor VEGFR1, and VEGFR2.
Fruquintinib is a selective inhibitor of VEGFRs, and we used it to research the results on the upkeep of pluripotency and differentiation potential of mESCs on this examine. Our outcomes confirmed that fruquintinib-treated cells expressed greater ranges of pluripotent markers, together with Oct4, Nanog, Sox2, and Esrrb below serum and leukemia inhibitory issue (LIF) situation, whereas the expression of phosphorylated Erk1/2 was restricted.
Mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (MEK) signaling inhibitor (PD0325901) and glycogen synthase kinase 3 (GSK3) signaling inhibitor (CHIR99021) (also referred to as 2i) allow cells to keep up naive pluripotency with LIF, and fruquintinib may promote cells to keep up naive pluripotent state even below serum/LIF situation, whereas VEGF addition limits the pluripotency traits in serum/LIF mESCs.
Moreover, fruquintinib might inhibit the three-germ layer institution in embryoid physique formation and keep the undifferentiated traits of mESCs, indicating that fruquintinib might promote the upkeep of naive pluripotency and inhibit early differentiation packages.
A Gene Expression Signature to Predict Nucleotide Excision Restore Defects and Novel Therapeutic Approaches
Nucleotide excision restore (NER) resolves DNA adducts, equivalent to these attributable to ultraviolet gentle. Poor NER (dNER) ends in the next mutation price that may predispose to most cancers growth and untimely ageing phenotypes.
Right here, we used isogenic dNER mannequin cell traces to determine a gene expression signature that may precisely predict purposeful NER capability in each cell traces and affected person samples. Critically, not one of the recognized NER poor cell traces harbored mutations in any NER genes, suggesting that the prevalence of NER defects might at present be underestimated.
Identification of compounds that induce the dNER gene expression signature led to the invention that NER may be functionally impaired by GSK3 inhibition, resulting in synergy when mixed with cisplatin remedy.
Moreover, we predicted and validated a number of novel medicine which are synthetically deadly with NER defects utilizing the dNER gene signature as a drug discovery platform. Taken collectively, our work supplies a dynamic predictor of NER operate that could be utilized for therapeutic stratification in addition to growth of novel organic insights in human tumors.
Cell floor integrin α5ß1 clustering negatively regulates receptor tyrosine kinase signaling in colorectal most cancers cells through glycogen synthase kinase 3
As a key course of throughout the tissue microenvironment, integrin signaling can affect cell purposeful responses to progress issue stimuli. We present right here that clustering of integrin α5ß1 on the plasma membrane of colorectal cancer-derived epithelial cells modulates their skill to answer stimulation by receptor tyrosine kinase (RTK)-activating progress elements EGF, NRG and HGF, via GSK3-mediated suppression of Akt pathway.
We noticed that integrin α5ß1 is misplaced from the membrane of poorly organized human colorectal tumors and that remedy with the integrin-clustering antibody P4G11 is enough to induce polarity in a mouse tumor xenograft mannequin.
Whereas including RTK progress elements (EGF, NRG and HGF) to polarized colorectal most cancers cells induced invasion and lack of monolayer formation in 2D and 3D, this pathological conduct might be blocked by P4G11. Phosphorylation of ErbB members of the family in addition to MET following EGF, NRG and HGF remedy was diminished in cells pretreated with P4G11.
Specializing in EGFR, we discovered that blockade of integrin α5ß1 elevated EGFR phosphorylation. Since exercise of a number of downstream kinase pathways have been altered by these numerous therapies, we employed computational machine studying strategies to establish crucial results. Partial least-squares discriminant evaluation recognized GSK3 as a serious regulator of EGFR pathway actions influenced by integrin α5ß1.
Furthermore, we used partial correlation evaluation to look at signaling pathway crosstalk downstream of EGF stimulation and located that integrin α5ß1 acts as a destructive regulator of the AKT signaling cascade downstream of EGFR, with GSK3 appearing as a key mediator. We experimentally validated these computational inferences by confirming that blockade of GSK3 exercise is enough to induce lack of polarity and enhance of oncogenic signaling within the colonic epithelial cells.
Hawthorn polyphenols, D-chiro-inositol, and epigallocatechin gallate exert a synergistic hypoglycemic impact
Hawthorn berry has been proved hypoglycemic impact as a result of presence of some α-glucosidase inhibitors. Herein, screening and figuring out of α-glucosidase inhibitors from hawthorn berry have been performed, and the outcomes confirmed polyphenols primarily containing quercetin (74.58%) and hyperioside (9.58%) have been chargeable for its bioactivity.
With a purpose to improve the hypoglycemic impact, the mixed glucose-lowering advanced (DEH) consisting of hawthorn polyphenols, D-chiro-inositol (DCI), and epigallocatechin gallate (EGCG) was ready, the place three elements exerted the synergistic hypoglycemic impact to boost glucose consumption and glycogen ranges and inhibit hepatic gluconeogenesis in IR-HepG2 cells.
In STZ/HFD-induced mice, DEH successfully improved insulin resistance, lowered fasting blood glucose (FBG) and hepatic gluconeogenesis, and elevated hepatic glycogen synthesis and storage through down-regulation of PI3K/Akt/FOXO1-mediated PEPCK and G6Pase and up-regulation of PI3K/Akt/GSK3-mediated GS activation within the liver. In abstract, these findings point out that DEH is a possible novel technique for the remedy of kind 2 diabetes.
PRACTICAL APPLICATIONS: Glucose-lowering advanced (DEH) with superior hypoglycemic impact, can successfully enhance the insulin resistance, cut back the fasting blood glucose, hepatic gluconeogenesis and enhance the hepatic glycogen synthesis and storage in mice, which represents a possible novel technique for the remedy of kind 2 diabetes.
Isoorientin inhibits epithelial-to-mesenchymal properties and most cancers stem-cell-like options in oral squamous cell carcinoma by blocking Wnt/β-catenin/STAT3 axis
Oral squamous cell carcinoma (OSCC) is among the many most prevalent cancers of the top and neck. This examine revealed that isoorientin attenuates OSCC cell stemness and epithelial-mesenchymal transition potential via the inhibition of JAK/sign transducer and activator of transcription 3 (STAT3) and Wnt/β-catenin signaling in cell traces. Our findings indicated that isoorientin is a possible inhibitor of β-catenin/STAT3 in vitro and in vivo.
We analyzed doable synergism between isoorientin and cisplatin in OSCC. A sulforhodamine B assay, colony formation assay, tumorsphere-formation assay, and Wnt reporter exercise assay have been used for figuring out cell invasion, cell migration, drug cytotoxicity, and cell viability with potential molecular mechanisms in vitro. Isoorientin lowered the expression of p-STAT3, β-catenin, and p-GSK3 in addition to downstream effectors TCF1/TCF7 and LEF1 and considerably lowered β-catenin colocalization within the nucleus.
Isoorientin markedly strengthened the cytotoxic results of cisplatin towards SAS and SCC-25. Due to this fact, combining isoorientin and cisplatin therapies can probably enhance the anticancer impact of cisplatin. Isoorientin inhibited the tumorigenicity and progress of OSCC via the abrogation of Wnt/β-catenin/STAT3 signaling in vivo.
 GSK3 alpha antibody |
|||
| 70R-49830 | Fitzgerald | 100 ul | EUR 286 |
|
Description: Purified Polyclonal GSK3 alpha antibody |
|||
GSK3 alpha antibody |
|||
| 70R-34164 | Fitzgerald | 100 ug | EUR 294 |
|
Description: Rabbit polyclonal GSK3 alpha antibody |
|||
 GSK3 alpha Antibody |
|||
| ABF6336 | Lifescience Market | 100 ug | EUR 525.6 |
GSK3 alpha Antibody |
|||
| abx033883-100g | Abbexa | 100 µg | EUR 281.25 |
GSK3 alpha Antibody |
|||
| abx033883-400ul | Abbexa | 400 ul | EUR 627.6 |
GSK3 alpha Antibody |
|||
| abx033883-80l | Abbexa | 80 µl | EUR 343.2 |
GSK3 alpha antibody |
|||
| 20R-1883 | Fitzgerald | 50 ug | EUR 269 |
|
Description: Rabbit polyclonal GSK3 alpha antibody |
|||
GSK3 alpha antibody |
|||
| 20R-2192 | Fitzgerald | 50 ug | EUR 269 |
|
Description: Rabbit polyclonal GSK3 alpha antibody |
|||
GSK3 alpha antibody |
|||
| 10R-1930 | Fitzgerald | 100 ul | EUR 468 |
|
Description: Mouse monoclonal GSK3 alpha antibody |
|||
GSK3 alpha antibody |
|||
| 10R-2025 | Fitzgerald | 100 ul | EUR 503 |
|
Description: Mouse monoclonal GSK3 alpha antibody |
|||
GSK3 alpha antibody |
|||
| 10R-2104 | Fitzgerald | 100 ul | EUR 468 |
|
Description: Mouse monoclonal GSK3 alpha antibody |
|||
GSK3 alpha Antibody |
|||
| abx012858-100g | Abbexa | 100 µg | EUR 237.5 |
GSK3 alpha Antibody |
|||
| 20-abx012858 | Abbexa |
|
|
GSK3 alpha Antibody |
|||
| abx012858-10g | Abbexa | 10 µg | EUR 43.75 |
GSK3 alpha Antibody |
|||
| abx012858-200g | Abbexa | 200 µg | EUR 312.5 |
GSK3 alpha Antibody |
|||
| abx010857-100g | Abbexa | 100 µg | Ask for price |
GSK3 alpha Antibody |
|||
| abx010857-100ul | Abbexa | 100 ul | EUR 493.2 |
GSK3 alpha Antibody |
|||
| abx010857-10g | Abbexa | 10 µg | EUR 362.5 |
GSK3 alpha Antibody |
|||
| abx010857-200g | Abbexa | 200 µg | Ask for price |
GSK3 alpha Antibody |
|||
| abx015750-100ul | Abbexa | 100 ul | EUR 493.2 |
GSK3 alpha Antibody |
|||
| abx015750-1mg | Abbexa | 1 mg | EUR 362.5 |
GSK3 alpha Antibody |
|||
| abx015751-100ul | Abbexa | 100 ul | EUR 493.2 |
GSK3 alpha Antibody |
|||
| abx015751-1mg | Abbexa | 1 mg | EUR 362.5 |
GSK3 alpha Antibody |
|||
| 20-abx133173 | Abbexa |
|
|
GSK3 alpha Antibody |
|||
| BF0391 | Affbiotech | 200ul | EUR 540 |
GSK3 alpha Antibody |
|||
| BF0391-100ul | Affinity Biosciences | 100ul | EUR 210 |
|
Description: WB,ELISA |
|||
GSK3 alpha Antibody |
|||
| BF0391-200ul | Affinity Biosciences | 200ul | Ask for price |
|
Description: WB,ELISA |
|||
GSK3 alpha Antibody |
|||
| BF0391-50ul | Affinity Biosciences | 50ul | EUR 150 |
|
Description: WB,ELISA |
|||
GSK3 alpha Antibody |
|||
| AF7813 | Affbiotech | 200ul | EUR 540 |
GSK3 alpha Antibody |
|||
| AF7813-100ul | Affinity Biosciences | 100ul | EUR 210 |
|
Description: WB,ELISA(peptide) |
|||
GSK3 alpha Antibody |
|||
| AF7813-200ul | Affinity Biosciences | 200ul | EUR 270 |
|
Description: WB,ELISA(peptide) |
|||
GSK3 alpha Antibody |
|||
| AF7813-50ul | Affinity Biosciences | 50ul | EUR 150 |
|
Description: WB,ELISA(peptide) |
|||
GSK3 alpha Antibody |
|||
| AF6336 | Affbiotech | 200ul | EUR 420 |
GSK3 alpha Antibody |
|||
| AF6336-100ul | Affinity Biosciences | 100ul | EUR 168 |
|
Description: WB,IHC,IP,ELISA(peptide) |
|||
GSK3 alpha Antibody |
|||
| AF6336-200ul | Affinity Biosciences | 200ul | EUR 210 |
|
Description: WB,IHC,IP,ELISA(peptide) |
|||
GSK3 alpha Antibody |
|||
| E10-20133 | EnoGene | 100μg/100μl | EUR 225 |
|
Description: Available in various conjugation types. |
|||
GSK3 alpha Antibody |
|||
| E10-20134 | EnoGene | 100μg/100μl | EUR 225 |
|
Description: Available in various conjugation types. |
|||
GSK3 alpha Antibody |
|||
| E18-6336-1 | EnoGene | 50μg/50μl | EUR 145 |
|
Description: Available in various conjugation types. |
|||
GSK3 alpha Antibody |
|||
| E18-6336-2 | EnoGene | 100μg/100μl | EUR 225 |
|
Description: Available in various conjugation types. |
|||
GSK3 alpha Antibody |
|||
| E38PA4666 | EnoGene | 100ug/100ul | EUR 225 |
 GSK3 Alpha Antibody |
|||
| MBS5314450-01mL | MyBiosource | 0.1mL | EUR 535 |
GSK3 Alpha Antibody |
|||
| MBS5314450-5x01mL | MyBiosource | 5x0.1mL | EUR 2270 |
GSK3 Alpha Antibody |
|||
| MBS5313788-01mg | MyBiosource | 0.1mg | EUR 420 |
GSK3 Alpha Antibody |
|||
| MBS5313788-5x01mg | MyBiosource | 5x0.1mg | EUR 1740 |
GSK3 alpha antibody |
|||
| MBS5309469-005mg | MyBiosource | 0.05mg | EUR 485 |
GSK3 alpha antibody |
|||
| MBS5309469-5x005mg | MyBiosource | 5x0.05mg | EUR 2045 |
GSK3 alpha antibody |
|||
| MBS5309650-005mg | MyBiosource | 0.05mg | EUR 485 |
GSK3 alpha antibody |
|||
| MBS5309650-5x005mg | MyBiosource | 5x0.05mg | EUR 2045 |
GSK3 alpha antibody |
|||
| MBS5310885-01mL | MyBiosource | 0.1mL | EUR 810 |
GSK3 alpha antibody |
|||
| MBS5310885-5x01mL | MyBiosource | 5x0.1mL | EUR 3505 |
GSK3 alpha Antibody |
|||
| MBS9611101-005mL | MyBiosource | 0.05mL | EUR 245 |
GSK3 alpha Antibody |
|||
| MBS9611101-01mL | MyBiosource | 0.1mL | EUR 305 |
GSK3 alpha Antibody |
|||
| MBS9611101-02mL | MyBiosource | 0.2mL | EUR 365 |
GSK3 alpha Antibody |
|||
| MBS9611101-5x02mL | MyBiosource | 5x0.2mL | EUR 1495 |
GSK3 alpha Antibody |
|||
| MBS850340-01mg | MyBiosource | 0.1mg | EUR 305 |
GSK3 alpha Antibody |
|||
| MBS850340-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 565 |
GSK3 alpha Antibody |
|||
| MBS850340-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 565 |
GSK3 alpha Antibody |
|||
| MBS850340-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 565 |
GSK3 alpha Antibody |
|||
| MBS850340-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 565 |
GSK3 alpha Antibody |
|||
| MBS9601905-01mL | MyBiosource | 0.1mL | EUR 260 |
GSK3 alpha Antibody |
|||
| MBS9601905-02mL | MyBiosource | 0.2mL | EUR 305 |
GSK3 alpha Antibody |
|||
| MBS9601905-5x02mL | MyBiosource | 5x0.2mL | EUR 1220 |
GSK3 alpha antibody |
|||
| MBS831258-01mL | MyBiosource | 0.1mL | EUR 855 |
GSK3 alpha antibody |
|||
| MBS831258-5x01mL | MyBiosource | 5x0.1mL | EUR 3695 |
GSK3 alpha antibody |
|||
| MBS831707-01mL | MyBiosource | 0.1mL | EUR 810 |
GSK3 alpha antibody |
|||
| MBS831707-5x01mL | MyBiosource | 5x0.1mL | EUR 3505 |
GSK3 alpha Antibody |
|||
| MBS8512363-005mg | MyBiosource | 0.05mg | EUR 235 |
GSK3 alpha Antibody |
|||
| MBS8512363-01mg | MyBiosource | 0.1mg | EUR 305 |
GSK3 alpha Antibody |
|||
| MBS8512363-01mLAF405M | MyBiosource | 0.1mL(AF405M) | EUR 465 |
GSK3 alpha Antibody |
|||
| MBS8512363-01mLAF546 | MyBiosource | 0.1mL(AF546) | EUR 465 |
GSK3 alpha Antibody |
|||
| MBS8512363-01mLAF750 | MyBiosource | 0.1mL(AF750) | EUR 465 |
GSK3 alpha Antibody |
|||
| MBS9504149-005mL | MyBiosource | 0.05mL | EUR 285 |
GSK3 alpha Antibody |
|||
| MBS9504149-01mL | MyBiosource | 0.1mL | EUR 385 |
GSK3 alpha Antibody |
|||
| MBS9504149-5x01mL | MyBiosource | 5x0.1mL | EUR 1590 |
GSK3 alpha Antibody |
|||
| MBS9435050-005mL | MyBiosource | 0.05mL | EUR 325 |
GSK3 alpha Antibody |
|||
| MBS9435050-01mL | MyBiosource | 0.1mL | EUR 445 |
GSK3 alpha Antibody |
|||
| MBS9435050-5x01mL | MyBiosource | 5x0.1mL | EUR 1860 |
GSK3 alpha Antibody |
|||
| MBS850040-01mg | MyBiosource | 0.1mg | EUR 305 |
GSK3 alpha Antibody |
|||
| MBS850040-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 565 |
GSK3 alpha Antibody |
|||
| MBS850040-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 565 |
GSK3 alpha Antibody |
|||
| MBS850040-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 565 |
GSK3 alpha Antibody |
|||
| MBS850040-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 565 |
 Anti-GSK3 alpha/GSK3A Antibody |
|||
| MBS1753069-01mg | MyBiosource | 0.1mg | EUR 450 |
Anti-GSK3 alpha/GSK3A Antibody |
|||
| MBS1753069-5x01mg | MyBiosource | 5x0.1mg | EUR 1870 |
) GSK3 alpha antibody (Ser21) |
|||
| 70R-37089 | Fitzgerald | 100 ug | EUR 344 |
|
Description: Rabbit Polyclonal GSK3 alpha antibody (Ser21) |
|||
GSK3 alpha antibody (Ser21) |
|||
| 70R-34163 | Fitzgerald | 100 ug | EUR 294 |
|
Description: Rabbit polyclonal GSK3 alpha antibody (Ser21) |
|||
) GSK3 Alpha Antibody (Ser21) |
|||
| MBS5313464-01mg | MyBiosource | 0.1mg | EUR 530 |
GSK3 Alpha Antibody (Ser21) |
|||
| MBS5313464-5x01mg | MyBiosource | 5x0.1mg | EUR 2235 |
 GSK3 alpha/beta antibody |
|||
| 70R-49831 | Fitzgerald | 100 ul | EUR 242 |
|
Description: Purified Polyclonal GSK3 alpha/beta antibody |
|||
GSK3 alpha/beta antibody |
|||
| 70R-51552 | Fitzgerald | 100 ul | EUR 286 |
|
Description: Purified Polyclonal GSK3 alpha/beta antibody |
|||
GSK3 alpha/beta antibody |
|||
| 70R-30578 | Fitzgerald | 100 ug | EUR 294 |
|
Description: Rabbit polyclonal GSK3 alpha/beta antibody |
|||
 GSK3 alpha/beta Antibody |
|||
| ABF6335 | Lifescience Market | 100 ug | EUR 525.6 |
GSK3 alpha/beta Antibody |
|||
| 29039-100ul | SAB | 100ul | EUR 302.4 |
 GSK3 alpha / beta Antibody |
|||
| 20-abx009185 | Abbexa |
|
|
 Antibody) GSK3 alpha (pS21) Antibody |
|||
| 20-abx009689 | Abbexa |
|
|
GSK3 alpha (pS21) Antibody |
|||
| abx010870-100ug | Abbexa | 100 ug | EUR 526.8 |
 GSK3 alpha/ beta Antibody |
|||
| DF6806 | Affbiotech | 200ul | EUR 420 |
GSK3 alpha/ beta Antibody |
|||
| DF6806-100ul | Affinity Biosciences | 100ul | EUR 168 |
|
Description: WB,IHC,ELISA(peptide) |
|||
GSK3 alpha/ beta Antibody |
|||
| DF6806-200ul | Affinity Biosciences | 200ul | EUR 210 |
|
Description: WB,IHC,ELISA(peptide) |
|||
GSK3 alpha/ beta Antibody |
|||
| AF6335 | Affbiotech | 200ul | EUR 420 |
GSK3 alpha/ beta Antibody |
|||
| AF6335-100ul | Affinity Biosciences | 100ul | EUR 168 |
|
Description: WB,IHC,IF/ICC,ELISA(peptide) |
|||
GSK3 alpha/ beta Antibody |
|||
| AF6335-200ul | Affinity Biosciences | 200ul | EUR 210 |
|
Description: WB,IHC,IF/ICC,ELISA(peptide) |
|||
 GSK3 alpha & beta Antibody |
|||
| GWB-52E33B | GenWay Biotech | 0.5 ml | Ask for price |
GSK3 alpha/beta Antibody |
|||
| E18-6335-1 | EnoGene | 50μg/50μl | EUR 145 |
|
Description: Available in various conjugation types. |
|||
GSK3 alpha/beta Antibody |
|||
| E18-6335-2 | EnoGene | 100μg/100μl | EUR 225 |
|
Description: Available in various conjugation types. |
|||
GSK3 alpha (pS21) Antibody |
|||
| E38PA1511 | EnoGene | 100ul | EUR 225 |
|
Description: Available in various conjugation types. |
|||
GSK3 alpha/beta Antibody |
|||
| E38PA1512 | EnoGene | 100ul | EUR 225 |
|
Description: Available in various conjugation types. |
|||
 GSK3 Alpha/beta Antibody |
|||
| MBS5314451-01mL | MyBiosource | 0.1mL | EUR 470 |
GSK3 Alpha/beta Antibody |
|||
| MBS5314451-5x01mL | MyBiosource | 5x0.1mL | EUR 1955 |
GSK3 Alpha/beta Antibody |
|||
| MBS5316168-01mL | MyBiosource | 0.1mL | EUR 535 |
GSK3 Alpha/beta Antibody |
|||
| MBS5316168-5x01mL | MyBiosource | 5x0.1mL | EUR 2270 |
GSK3 alpha/beta Antibody |
|||
| MBS9601904-01mL | MyBiosource | 0.1mL | EUR 260 |
GSK3 alpha/beta Antibody |
|||
| MBS9601904-02mL | MyBiosource | 0.2mL | EUR 305 |
GSK3 alpha/beta Antibody |
|||
| MBS9601904-5x02mL | MyBiosource | 5x0.2mL | EUR 1220 |
GSK3 alpha (pS21) Antibody |
|||
| MBS8580644-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 465 |
GSK3 alpha (pS21) Antibody |
|||
| MBS8580644-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 465 |
GSK3 alpha (pS21) Antibody |
|||
| MBS8580644-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 465 |
GSK3 alpha/beta Antibody |
|||
| MBS8580645-01mL | MyBiosource | 0.1mL | EUR 305 |
GSK3 alpha/beta Antibody |
|||
| MBS8580645-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 465 |
GSK3 alpha/beta Antibody |
|||
| MBS8580645-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 465 |
GSK3 alpha/beta Antibody |
|||
| MBS8580645-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 465 |
GSK3 alpha/beta Antibody |
|||
| MBS8580645-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 465 |
GSK3 alpha (pS21) Antibody |
|||
| MBS8580644-01mL | MyBiosource | 0.1mL | EUR 305 |
GSK3 alpha (pS21) Antibody |
|||
| MBS8580644-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 465 |
GSK3 alpha/beta Antibody |
|||
| MBS8512362-005mg | MyBiosource | 0.05mg | EUR 235 |
GSK3 alpha/beta Antibody |
|||
| MBS8512362-01mg | MyBiosource | 0.1mg | EUR 305 |
GSK3 alpha/beta Antibody |
|||
| MBS8512362-01mLAF405M | MyBiosource | 0.1mL(AF405M) | EUR 465 |
GSK3 alpha/beta Antibody |
|||
| MBS8512362-01mLAF546 | MyBiosource | 0.1mL(AF546) | EUR 465 |
GSK3 alpha/beta Antibody |
|||
| MBS8512362-01mLAF750 | MyBiosource | 0.1mL(AF750) | EUR 465 |
GSK3 alpha/beta Antibody |
|||
| MBS9503444-005mL | MyBiosource | 0.05mL | EUR 285 |
GSK3 alpha/beta Antibody |
|||
| MBS9503444-01mL | MyBiosource | 0.1mL | EUR 385 |
GSK3 alpha/beta Antibody |
|||
| MBS9503444-5x01mL | MyBiosource | 5x0.1mL | EUR 1590 |
GSK3 alpha/beta Antibody |
|||
| MBS9412082-01mL | MyBiosource | 0.1mL | EUR 305 |
Thus, isoorientin disrupted the β-catenin signaling pathway via the inactivation of STAT3 signaling. In conclusion, focusing on OSCC-SC-mediated stemness with isoorientin to eradicate OSCC-SCs could also be an efficient technique for stopping relapse and metastasis of OSCC and offering long-term survival advantages.
